Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    US Begins Phase 1 Clinical Trial of Universal Flu Vaccine

    By Global Biodefense StaffJune 28, 2022
    A subject volunteer for the trial of candidate universal flu vaccine BPL-1357, Credit: NIAID
    Share
    Facebook LinkedIn Reddit Email

    A Phase 1 clinical trial of a novel influenza vaccine has begun inoculating healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland.

    The placebo-controlled trial will test the safety of a candidate vaccine, BPL-1357, and its ability to prompt immune responses. The vaccine candidate was developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID).

    The single-site trial can enroll up to 100 people aged 18 to 55 years and is led by NIAID investigator Matthew J. Memoli, M.D.

    BPL-1357 is a whole-virus vaccine made up of four strains of non-infectious, chemically inactivated, low-pathogenicity avian flu virus. A study in animals, led by NIAID investigator Jeffery K. Taubenberger, M.D., Ph.D., and posted online as a pre-print, found that all mice receiving two doses of BPL-1357 vaccine delivered either intramuscularly or intranasally survived later exposure to lethal doses of each of six different influenza virus strains, including subtypes that were not included in the vaccine. Similar results were obtained in challenge experiments with BPL-1357-vaccinated ferrets. 

    “Influenza vaccines that can provide long-lasting protection against a wide range of seasonal influenza viruses as well as those with pandemic potential would be invaluable public health tools,” said NIAID Director Anthony S. Fauci, M.D. “The scientific community is making progress on this pressing global health priority. The BPL-1357 candidate influenza vaccine being tested in this clinical trial performed very well in pre-clinical studies and we look forward to learning how it performs in people.” 

    In the Phase 1 trial, volunteers will be randomized in a 1:1:1 ratio into three groups and will receive two doses of placebo or vaccine spaced 28 days apart. Group A participants receive BPL-1357 intramuscularly along with intranasal saline placebo; Group B will receive doses of the candidate vaccine intranasally along with intramuscular placebo; volunteers in Group C receive intramuscularly and intranasally delivered placebo at both visits to the clinic. Neither the study clinicians nor the volunteers know the group assignments. Volunteers must not have received any type of flu vaccination in the eight weeks prior to enrollment and must agree to forego seasonal flu vaccination for approximately two months after the second vaccine (or placebo) dose. 

    “With the BPL-1357 vaccine, especially when given intranasally, we are attempting to induce a comprehensive immune response that closely mimics immunity gained following a natural influenza infection,” said Dr. Memoli. “This is very different than nearly all other vaccines for influenza or other respiratory viruses, which focus on inducing immunity to a single viral antigen and often do not induce mucosal immunity.” 

    The study duration for each participant is approximately seven months. In addition to the two clinic visits to receive vaccine (or placebo), volunteers will be asked to return to the clinic seven times to provide blood and nasal mucosal samples that will be used by the investigators to detect and characterize immune responses. 

    “Our study will examine the safety of BPL-1357 and also will allow us to assess the importance of mucosal immunity against flu and whether a strategy of inducing both the cellular and antibody arms of the immune system can provide broader protection against the ever-changing influenza virus,” he added. 

    For additional information about the trial, visit ClinicalTrials.gov and search on the trial identifier NCT05027932. 


    Related Reading:

    U.S. Invests $36.3M in Pan-Coronavirus Vaccine Development

    Hotel Influenza: Research Heats Up on Universal Flu Vaccines

    Senator Markey Introduces Legislation to Invest $1 Billion in Universal Coronavirus Vaccine

    1918 Influenza Provides Warning for Potential Future Pandemic Reemergence

    Clinical Trials Drug Delivery Systems Influenza NIAID NIH Universal Flu Vaccine
    Share. Facebook LinkedIn Reddit Email
    Previous ArticlePoliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps
    Next Article Biodefense Headlines – 5 July 2022

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Healthcare Workers Express Outrage at Flawed CDC Mask Guidance

    September 18, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    NIAID Seeks to Improve Computational Models of Influenza Immunity

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.